Investigators aim to establish an optimal dose and explore CER-1236's safety and preliminary anti-tumor activity.

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with ...

CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses ...

Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

In this single-arm trial, the median overall survival (OS) observed was 4.0 months (95% CI: 2.5-7.2) among all 64 adults in the primary efficacy analysis based on the Kaplan-Meier estimate. The median ...

Therapeutic efforts in acute myeloid leukemia (AML ... Researchers identified 55 distinct hematopoietic cell states across the dataset. All leukemia cells were projected onto these reference ...

Given that not all ... differentiation anomalies. Using bulk RNA sequencing data from more than 1,200 AML patient samples, the Toronto team estimated the abundance of each leukemia cell state ...

A new study has identified a novel strategy for treating acute myelogenous leukemia (AML ... all its subtypes share a common feature: impaired differentiation of myeloid progenitor cells in ...

Though AML is ... promyelocytic leukemia (APL)—is already treated this way using a pair of drugs (all-trans retinoic acid and arsenic trioxide) that shove APL cells down the differentiation ...

Acute myeloid leukemia ... abnormal blood cells, which reduces the number of healthy blood cells. AML only accounts for roughly 1% of all cancers and approximately 1 in 3 leukemia cases in ...